Developer docs
API playgroundTry for free, no card

Search company profiles

Ekso Bionics

Full company profile

uuid0004itr

Namestring
Ekso Bionics
Legal namestring
Ekso Bionics Europe GmbH & Ekso Bionics USA
Websiteurl
eksobionics.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Ekso Bionics is a publicly-traded (NASDAQ: EKSO) medical device company founded in 2005 and headquartered in the San Rafael/Richmond, California area that develops powered lower-limb and upper-body exoskeletons for clinical rehabilitation and industrial workplace applications. The core medical product line consists of the EksoNR robotic exoskeleton (FDA-cleared for stroke, acquired brain injury, multiple sclerosis, and spinal cord injury, with proprietary GaitCoach real-time gait-feedback software), the Ekso Indego Therapy clinical gait-training device, and the Ekso Indego Personal personal-use exoskeleton for individuals with T3-L5 spinal cord injury. The company also sells the Ekso EVO upper-body industrial exoskeleton for overhead work and lifting, and holds exclusive U.S. distribution rights to MediTouch's BalanceTutor perturbation treadmill for balance and fall-prevention training.

Revenue is generated primarily through capital-equipment hardware sales to rehabilitation hospitals and clinics (via a direct enterprise field-sales motion and a 500+ center certified network globally), supplemented by clinical training and technical support services and by personal-device sales fulfilled through the U.S. Department of Veterans Affairs and Medicare reimbursement pathways established under the brace benefit category as of April 2024. Industrial products are sold directly to employers in construction, manufacturing, and logistics, while the MediTouch BalanceTutor provides additional distribution-margin revenue. The company has been unprofitable, has run four dilutive equity raises totaling roughly $20M between January 2024 and January 2026, and in December 2025 announced — closing in May 2026 — a merger of Applied Digital's cloud-computing business into the public entity to form ChronoScale Corporation, with Applied Digital retaining approximately 97% ownership.

Short descriptiontext

Ekso Bionics develops powered exoskeletons for clinical neurorehabilitation (EksoNR, Indego Therapy, Indego Personal) and industrial upper-body support (Ekso EVO), selling to hospitals, the VA, Medicare-eligible individuals with spinal cord injury, and industrial employers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Rafael, United States
HQ citystring
San Rafael
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable robotic exoskeletons, medical rehabilitation devices, industrial exoskeleton systems, neurorehabilitation robotics, gait training equipment
Industry3 codes
1Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics)
CodeHLAHAMAJPrimaryYes
2Prosthetics/Orthotics Rehab & Amputee Rehabilitation
CodeHSADAIANPrimaryNo
3Compression Therapy & Lymphedema DME (Garments, Pneumatic Pumps)
CodeHLAHAMAHPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Rehabilitation Robotics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Medical Exoskeleton Hardware Sales
TypeHardware Sales
Description

Sale of EksoNR, Ekso Indego Therapy, and Ekso Indego Personal exoskeleton devices to rehabilitation centers, hospitals, and individuals. Q3 2025 revenue was $4.2 million.

globenewswire.com
2Clinical Training and Support Services
TypeProfessional Services
Description

Training programs for clinical staff, certified Ekso Indego Specialist certification, and ongoing technical support for deployed devices.

eksobionics.com
3Veterans Affairs (VA) Device Coverage
TypeHardware Sales
Description

VA policy allows Ekso Indego Personal to be issued to qualified veterans at no cost to the veteran. Reimbursement from government healthcare programs.

eksobionics.com
4Medicare Personal Exoskeleton Coverage
TypeHardware Sales
Description

As of April 2024, CMS established Medicare payment level for personal exoskeletons confirming coverage within brace benefit category for eligible individuals.

eksobionics.com
5Distribution Revenue (BalanceTutor)
TypeHardware Sales
Description

Exclusive U.S. distributor of MediTouch's BalanceTutor rehabilitation system, generating revenue from sales and distribution of the perturbation treadmill system.

globenewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Ekso Indego Personal - Personal Use Exoskeleton
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Device cost not publicly disclosed. Medicare coverage available for eligible individuals with spinal cord injuries (T3-L5).

eksobionics.com
2Ekso Indego Personal - VA Coverage
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

U.S. Department of Veterans Affairs provides Ekso Indego Personal to qualified veterans at no cost under revised VA policy.

eksobionics.com
3Clinical Rehabilitation Products
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

EksoNR and Ekso Indego Therapy sold to rehabilitation centers. Pricing not publicly disclosed - quote-based enterprise sales.

eksobionics.com
4Ekso EVO Industrial Exoskeleton
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Industrial exoskeleton for workplace injury prevention. Pricing not publicly disclosed - direct enterprise sales.

eksobionics.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Ekso Indego Personal
Description

A powered lower limb exoskeleton for individuals with spinal cord injuries (T3-L5) enabling independent walking at home and in the community. Weighs 31 lbs (14 kg), FDA-cleared, available through Medicare.

eksobionics.com
+4 more records
Core offering1 text field

Ekso Bionics designs, develops, manufactures, and sells wearable bionic exoskeletons for medical rehabilitation and industrial workplace use. Its medical line (EksoNR, Ekso Indego Therapy, Ekso Indego Personal) provides powered lower-limb assistance for patients recovering from stroke, acquired brain injury, multiple sclerosis, and spinal cord injury, while the Ekso EVO upper-body exoskeleton serves industrial employers seeking to reduce workplace injuries from overhead work and lifting. The company also exclusively distributes the MediTouch BalanceTutor perturbation treadmill in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 1,200-step increase in walking capacity demonstrated with EksoNR exoskeleton
+2 more records
Product overview1 text field

Ekso Bionics offers a portfolio of wearable bionic exoskeletons for both medical/rehabilitation and industrial applications. The medical portfolio includes EksoNR (rehabilitation exoskeleton FDA-cleared for stroke, ABI, MS, and SCI with GaitCoach software), Ekso Indego Therapy (clinical gait training), and Ekso Indego Personal (home/community use for SCI patients T3-L5). The industrial line features Ekso EVO (upper-body workplace exoskeleton). The company also distributes MediTouch's BalanceTutor perturbation treadmill and provides cloud analytics via EksoPulse. Past products include EksoVest and the military HULC exoskeleton. All products share core exoskeleton technology with modular designs, sensors, and real-time control systems.

Product and service6 records
1EksoNR
CategoryMedical Rehabilitation Exoskeleton
Description

A robotic exoskeleton for rehabilitation settings, FDA-cleared for stroke, acquired brain injury, multiple sclerosis (MS), and spinal cord injury (SCI). Features GaitCoach software with real-time gait deviation detection and intelligent feedback, supports over 200 published clinical articles, and enables therapists to deliver high-intensity, repetitive gait training.

2Ekso Indego Therapy
CategoryMedical Rehabilitation Exoskeleton
Description

An adjustable, lower-limb powered exoskeleton for clinical rehabilitation settings. Enables individualized gait therapy for patients with lower extremity weakness or paralysis from spinal cord injury or stroke, featuring a modular design and a wireless iOS application for real-time therapist controls and patient data capture.

3Ekso Indego Personal
CategoryPersonal Mobility Exoskeleton
Description

A powered lower limb exoskeleton enabling individuals with spinal cord injuries (T3-L5) to stand and walk independently at home and in the community. Features modular quick-connect components, weighs 31 lbs (14 kg), and includes a wireless iOS/Android app for real-time control and session data tracking.

4Ekso EVO
CategoryIndustrial Exoskeleton
Description

An upper-body wearable industrial exoskeleton designed to increase safety, productivity, and reduce injuries to the neck, shoulder, and back. Described as the world's most lightweight, durable, assistive industrial exoskeleton with maximum degree of freedom, used for overhead work and heavy lifting in construction, manufacturing, automotive, and logistics.

5BalanceTutor
CategoryRehabilitation Equipment (Distributed)
Description

An FDA-registered advanced multidirectional perturbation treadmill for rehabilitation. Engineered by MediTouch, it promotes reactive response training for improved balance using patented perturbation technology and multiple force and movement sensors. Ekso Bionics is the authorized exclusive U.S. distributor.

6AI-Enabled Rehabilitation Exoskeleton
CategoryMedical Rehabilitation Exoskeleton
Description

An AI-enabled rehabilitation exoskeleton developed by Ekso Bionics and launched in March 2026, reflecting the company's collaboration with NVIDIA to accelerate AI integration in wearable robotics.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-29
Description

Applied Digital proposed business combination with EKSO Bionics to launch ChronoScale, an accelerated compute platform for AI workloads. The transaction involved spinning out Applied Digital's cloud business to merge with Ekso Bionics Holdings. Applied Digital retained ~97% ownership of the combined entity. The deal closed May 5, 2026, with ChronoScale trading under ticker CHRN.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-04
Description

Ekso Bionics became the exclusive U.S. distributor of MediTouch's BalanceTutor rehabilitation system. BalanceTutor is an FDA registered advanced multidirectional perturbation treadmill for reactive balance and fall-prevention training. The partnership expands Ekso's clinical rehabilitation portfolio to address balance training alongside existing gait exoskeleton offerings.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-01
Description

Ekso Bionics Holdings collaborated with NVIDIA in May 2025 to accelerate AI integration in wearable robotics. The collaboration focuses on advancing AI capabilities in exoskeleton technology, leveraging NVIDIA's computing platforms for enhanced robotics performance.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hocoma — now part of DIH Medical — is a global leader in robotic rehabilitation with the Lokomat treadmill-based gait trainer and Armeo upper-limb devices. It competes head-to-head with EksoNR in clinical neurorehabilitation settings and is the most-established player in robotic gait training.

TypeBroad incumbent
Description

Ottobock is a global leader in prosthetics, orthotics, and now exoskeletons (including the acquired SuitX industrial line). As a much larger, established medical-device company, it competes with Ekso across both rehabilitation and industrial exoskeleton categories with deeper resources and a global distribution network.

TypeDirect peer
Description

Bionik Laboratories produces robotic rehabilitation devices including the InMotion ARM and InMOTO WELL, focused on upper-limb and gait therapy in clinical settings. It is a smaller, sub-scale pure-play competitor in the same rehabilitation robotics category as Ekso Bionics.

TypeDirect peer
Description

ReWalk is the closest direct competitor to Ekso Bionics, also producing FDA-cleared powered exoskeletons (ReWalk Personal 6.0) for spinal cord injury ambulation and a clinical rehabilitation device. Both companies target the same SCI patient population, compete for VA and CMS reimbursement pathways, and sell to overlapping rehabilitation centers.

TypeEmerging player
Description

MindMaze develops digital neurotherapeutics and AI-driven neurorehabilitation platforms for stroke and brain injury recovery. It overlaps with Ekso's ABI and stroke rehabilitation focus through a software-first approach rather than powered exoskeletons, making it a partial-overlap emerging competitor.

TypeDirect peer
Description

Sarcos developed the Guardian XO and other industrial exoskeletons for worker augmentation, directly competing with Ekso EVO in the industrial/workplace safety segment. Both target employers seeking to reduce musculoskeletal injuries in construction, manufacturing, and logistics.

TypeDirect peer
Description

German Bionic produces the Cray X and Apogee+ connected industrial exoskeletons for logistics, construction, and manufacturing workers. It directly competes with Ekso EVO in the workplace-assistive exoskeleton market, particularly across European enterprises.

TypeDirect peer
Description

Cyberdyne develops the HAL (Hybrid Assistive Limb) wearable cyborg exoskeleton, with both medical (SCI, stroke) and industrial applications. It directly parallels Ekso's two-segment strategy of rehabilitation and workplace exoskeletons and is a key competitor in Japan and Asia.

TypeBroad incumbent
Description

Medtronic is a global medical-device incumbent with adjacent presence in neuromodulation, brain therapies, and rehabilitation-adjacent technologies. While not a direct exoskeleton competitor at scale, it competes for hospital neurology and rehabilitation budgets and could expand into the category.

TypeBroad incumbent
Description

Abbott is a broad medical-device and diagnostics incumbent with significant neurology and rehabilitation-adjacent product lines. As a large-cap peer in the neurorehabilitation devices market, it competes for hospital purchasing dollars and could potentially enter robotic exoskeleton therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ekso Bionics

Medical Rehabilitation Roboticseksobionics.com

Ekso Bionics develops powered exoskeletons for clinical neurorehabilitation (EksoNR, Indego Therapy, Indego Personal) and industrial upper-body support (Ekso EVO), selling to hospitals, the VA, Medicare-eligible individuals with spinal cord injury, and industrial employers.

What Ekso Bionics does

Ekso Bionics is a publicly-traded (NASDAQ: EKSO) medical device company founded in 2005 and headquartered in the San Rafael/Richmond, California area that develops powered lower-limb and upper-body exoskeletons for clinical rehabilitation and industrial workplace applications. The core medical product line consists of the EksoNR robotic exoskeleton (FDA-cleared for stroke, acquired brain injury, multiple sclerosis, and spinal cord injury, with proprietary GaitCoach real-time gait-feedback software), the Ekso Indego Therapy clinical gait-training device, and the Ekso Indego Personal personal-use exoskeleton for individuals with T3-L5 spinal cord injury. The company also sells the Ekso EVO upper-body industrial exoskeleton for overhead work and lifting, and holds exclusive U.S. distribution rights to MediTouch's BalanceTutor perturbation treadmill for balance and fall-prevention training.

Revenue is generated primarily through capital-equipment hardware sales to rehabilitation hospitals and clinics (via a direct enterprise field-sales motion and a 500+ center certified network globally), supplemented by clinical training and technical support services and by personal-device sales fulfilled through the U.S. Department of Veterans Affairs and Medicare reimbursement pathways established under the brace benefit category as of April 2024. Industrial products are sold directly to employers in construction, manufacturing, and logistics, while the MediTouch BalanceTutor provides additional distribution-margin revenue. The company has been unprofitable, has run four dilutive equity raises totaling roughly $20M between January 2024 and January 2026, and in December 2025 announced — closing in May 2026 — a merger of Applied Digital's cloud-computing business into the public entity to form ChronoScale Corporation, with Applied Digital retaining approximately 97% ownership.

Ekso Bionics firmographics

Firmographics
Name
Ekso Bionics
Legal name
Ekso Bionics Europe GmbH & Ekso Bionics USA
Website
https://eksobionics.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Ekso Bionics develops powered exoskeletons for clinical neurorehabilitation (EksoNR, Indego Therapy, Indego Personal) and industrial upper-body support (Ekso EVO), selling to hospitals, the VA, Medicare-eligible individuals with spinal cord injury, and industrial employers.
Ownership category
akta.pro rank

Ekso Bionics industry classification

Industry
Product category
Medical Rehabilitation Robotics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics) (HLAHAMAJ)
akta.pro secondary industries
Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN), Compression Therapy & Lymphedema DME (Garments, Pneumatic Pumps) (HLAHAMAH)

Keywords

  • Wearable robotic exoskeletons
  • Medical rehabilitation devices
  • Industrial exoskeleton systems
  • Neurorehabilitation robotics
  • Gait training equipment

Where Ekso Bionics is headquartered

Location

Headquarters

HQ city
San Rafael
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Ekso Bionics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Exoskeleton Hardware Sales: Sale of EksoNR, Ekso Indego Therapy, and Ekso Indego Personal exoskeleton devices to rehabilitation centers, hospitals, and individuals. Q3 2025 revenue was $4.2 million.
  2. Clinical Training and Support Services: Training programs for clinical staff, certified Ekso Indego Specialist certification, and ongoing technical support for deployed devices.
  3. Veterans Affairs (VA) Device Coverage: VA policy allows Ekso Indego Personal to be issued to qualified veterans at no cost to the veteran. Reimbursement from government healthcare programs.
  4. Medicare Personal Exoskeleton Coverage: As of April 2024, CMS established Medicare payment level for personal exoskeletons confirming coverage within brace benefit category for eligible individuals.
  5. Distribution Revenue (BalanceTutor): Exclusive U.S. distributor of MediTouch's BalanceTutor rehabilitation system, generating revenue from sales and distribution of the perturbation treadmill system.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractEkso Indego Personal - Personal Use Exoskeleton
One time/ perpetual licenseMulti-year contractEkso Indego Personal - VA Coverage
One time/ perpetual licenseMulti-year contractClinical Rehabilitation Products
One time/ perpetual licenseMulti-year contractEkso EVO Industrial Exoskeleton

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Ekso Bionics product offering

Product offering

Core offering

Ekso Bionics designs, develops, manufactures, and sells wearable bionic exoskeletons for medical rehabilitation and industrial workplace use. Its medical line (EksoNR, Ekso Indego Therapy, Ekso Indego Personal) provides powered lower-limb assistance for patients recovering from stroke, acquired brain injury, multiple sclerosis, and spinal cord injury, while the Ekso EVO upper-body exoskeleton serves industrial employers seeking to reduce workplace injuries from overhead work and lifting. The company also exclusively distributes the MediTouch BalanceTutor perturbation treadmill in the United States.

Product overview

Ekso Bionics offers a portfolio of wearable bionic exoskeletons for both medical/rehabilitation and industrial applications. The medical portfolio includes EksoNR (rehabilitation exoskeleton FDA-cleared for stroke, ABI, MS, and SCI with GaitCoach software), Ekso Indego Therapy (clinical gait training), and Ekso Indego Personal (home/community use for SCI patients T3-L5). The industrial line features Ekso EVO (upper-body workplace exoskeleton). The company also distributes MediTouch's BalanceTutor perturbation treadmill and provides cloud analytics via EksoPulse. Past products include EksoVest and the military HULC exoskeleton. All products share core exoskeleton technology with modular designs, sensors, and real-time control systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Ekso Indego Personal: A powered lower limb exoskeleton for individuals with spinal cord injuries (T3-L5) enabling independent walking at home and in the community. Weighs 31 lbs (14 kg), FDA-cleared, available through Medicare.
  • Ekso Indego Therapy
  • EksoNR
  • Ekso EVO
  • BalanceTutor

Products and services

  • EksoNR A robotic exoskeleton for rehabilitation settings, FDA-cleared for stroke, acquired brain injury, multiple sclerosis (MS), and spinal cord injury (SCI). Features GaitCoach software with real-time gait deviation detection and intelligent feedback, supports over 200 published clinical articles, and enables therapists to deliver high-intensity, repetitive gait training.
  • Ekso Indego Therapy An adjustable, lower-limb powered exoskeleton for clinical rehabilitation settings. Enables individualized gait therapy for patients with lower extremity weakness or paralysis from spinal cord injury or stroke, featuring a modular design and a wireless iOS application for real-time therapist controls and patient data capture.
  • Ekso Indego Personal A powered lower limb exoskeleton enabling individuals with spinal cord injuries (T3-L5) to stand and walk independently at home and in the community. Features modular quick-connect components, weighs 31 lbs (14 kg), and includes a wireless iOS/Android app for real-time control and session data tracking.
  • Ekso EVO An upper-body wearable industrial exoskeleton designed to increase safety, productivity, and reduce injuries to the neck, shoulder, and back. Described as the world's most lightweight, durable, assistive industrial exoskeleton with maximum degree of freedom, used for overhead work and heavy lifting in construction, manufacturing, automotive, and logistics.
  • BalanceTutor An FDA-registered advanced multidirectional perturbation treadmill for rehabilitation. Engineered by MediTouch, it promotes reactive response training for improved balance using patented perturbation technology and multiple force and movement sensors. Ekso Bionics is the authorized exclusive U.S. distributor.
  • AI-Enabled Rehabilitation Exoskeleton An AI-enabled rehabilitation exoskeleton developed by Ekso Bionics and launched in March 2026, reflecting the company's collaboration with NVIDIA to accelerate AI integration in wearable robotics.

Quantifiable outcome

  • 1,200-step increase in walking capacity demonstrated with EksoNR exoskeleton
  • +2 more outcomes

Companies that use Ekso Bionics

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Ekso Bionics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ekso Bionics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Applied Digital CorporationflagshipStrategic or Co-development Partner · 29 December 2025Applied Digital proposed business combination with EKSO Bionics to launch ChronoScale, an accelerated compute platform for AI workloads. The transaction involved spinning out Applied Digital's cloud business to merge with Ekso Bionics Holdings. Applied Digital retained ~97% ownership of the combined entity. The deal closed May 5, 2026, with ChronoScale trading under ticker CHRN.
  • MediTouch Inc.coreChannel Partner/ Reseller/ Distributor · 4 December 2025Ekso Bionics became the exclusive U.S. distributor of MediTouch's BalanceTutor rehabilitation system. BalanceTutor is an FDA registered advanced multidirectional perturbation treadmill for reactive balance and fall-prevention training. The partnership expands Ekso's clinical rehabilitation portfolio to address balance training alongside existing gait exoskeleton offerings.
  • NVIDIAcoreTechnology or Integration · 1 May 2025Ekso Bionics Holdings collaborated with NVIDIA in May 2025 to accelerate AI integration in wearable robotics. The collaboration focuses on advancing AI capabilities in exoskeleton technology, leveraging NVIDIA's computing platforms for enhanced robotics performance.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Ekso Bionics competitors and assessment

Company assessment

Direct peers

  • Hocoma (DIH Medical): Hocoma — now part of DIH Medical — is a global leader in robotic rehabilitation with the Lokomat treadmill-based gait trainer and Armeo upper-limb devices. It competes head-to-head with EksoNR in clinical neurorehabilitation settings and is the most-established player in robotic gait training.
  • Bionik Laboratories: Bionik Laboratories produces robotic rehabilitation devices including the InMotion ARM and InMOTO WELL, focused on upper-limb and gait therapy in clinical settings. It is a smaller, sub-scale pure-play competitor in the same rehabilitation robotics category as Ekso Bionics.
  • ReWalk Robotics: ReWalk is the closest direct competitor to Ekso Bionics, also producing FDA-cleared powered exoskeletons (ReWalk Personal 6.0) for spinal cord injury ambulation and a clinical rehabilitation device. Both companies target the same SCI patient population, compete for VA and CMS reimbursement pathways, and sell to overlapping rehabilitation centers.
  • Sarcos Technology and Robotics: Sarcos developed the Guardian XO and other industrial exoskeletons for worker augmentation, directly competing with Ekso EVO in the industrial/workplace safety segment. Both target employers seeking to reduce musculoskeletal injuries in construction, manufacturing, and logistics.
  • German Bionic: German Bionic produces the Cray X and Apogee+ connected industrial exoskeletons for logistics, construction, and manufacturing workers. It directly competes with Ekso EVO in the workplace-assistive exoskeleton market, particularly across European enterprises.
  • Cyberdyne: Cyberdyne develops the HAL (Hybrid Assistive Limb) wearable cyborg exoskeleton, with both medical (SCI, stroke) and industrial applications. It directly parallels Ekso's two-segment strategy of rehabilitation and workplace exoskeletons and is a key competitor in Japan and Asia.

Broad incumbents

  • Ottobock: Ottobock is a global leader in prosthetics, orthotics, and now exoskeletons (including the acquired SuitX industrial line). As a much larger, established medical-device company, it competes with Ekso across both rehabilitation and industrial exoskeleton categories with deeper resources and a global distribution network.
  • Medtronic: Medtronic is a global medical-device incumbent with adjacent presence in neuromodulation, brain therapies, and rehabilitation-adjacent technologies. While not a direct exoskeleton competitor at scale, it competes for hospital neurology and rehabilitation budgets and could expand into the category.
  • Abbott: Abbott is a broad medical-device and diagnostics incumbent with significant neurology and rehabilitation-adjacent product lines. As a large-cap peer in the neurorehabilitation devices market, it competes for hospital purchasing dollars and could potentially enter robotic exoskeleton therapy.

Emerging players

  • MindMaze: MindMaze develops digital neurotherapeutics and AI-driven neurorehabilitation platforms for stroke and brain injury recovery. It overlaps with Ekso's ABI and stroke rehabilitation focus through a software-first approach rather than powered exoskeletons, making it a partial-overlap emerging competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Ekso Bionics social profiles

Digital presence

Ekso Bionics compliance and trust

Trust signal

Compliance4 records

Ekso Bionics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ekso Bionics leadership team

Management profile

Number of profiles

Profiles5 records

Ekso Bionics funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ekso Bionics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ekso Bionics

What does Ekso Bionics do?

Ekso Bionics designs, develops, manufactures, and sells wearable bionic exoskeletons for medical rehabilitation and industrial workplace use. Its medical line (EksoNR, Ekso Indego Therapy, Ekso Indego Personal) provides powered lower-limb assistance for patients recovering from stroke, acquired brain injury, multiple sclerosis, and spinal cord injury, while the Ekso EVO upper-body exoskeleton serves industrial employers seeking to reduce workplace injuries from overhead work and lifting. The company also exclusively distributes the MediTouch BalanceTutor perturbation treadmill in the United States.

Is Ekso Bionics a public or private company?

Ekso Bionics is a public company. It is classified as public and is currently operating.

When was Ekso Bionics founded?

Ekso Bionics was founded in 2005. It employs 101 to 250 people.

Where is Ekso Bionics based?

Ekso Bionics is headquartered in San Rafael, United States, in the North America region.

How does Ekso Bionics make money?

Five revenue lines are on record. Medical Exoskeleton Hardware Sales are the primary driver. The others are clinical Training and Support Services, veterans Affairs (VA) Device Coverage, medicare Personal Exoskeleton Coverage and distribution Revenue (BalanceTutor).

Who are Ekso Bionics's main competitors?

Direct peers on record are Hocoma (DIH Medical), Bionik Laboratories, ReWalk Robotics, Sarcos Technology and Robotics, German Bionic and Cyberdyne. Broad incumbents are Ottobock, Medtronic and Abbott. MindMaze is listed as an emerging player.

Does Ekso Bionics have an API?

No public API is recorded for Ekso Bionics.

What industry is Ekso Bionics in?

Ekso Bionics's product category is Medical Rehabilitation Robotics. Its primary akta.pro industry code is HLAHAMAJ, Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics), with a secondary code of HSADAIAN, Prosthetics/Orthotics Rehab & Amputee Rehabilitation. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsChronoScale (NASDAQ: CHRN) lines up $1 billion run-rate after Ekso saleChronoScale completed its Ekso Bionics sale on September 30, 2026, and signed expanded agreements with existing and new AI infrastructure customers. The company projects annualized run-rate revenue of $1 billion by calendar Q3 2027, based on current contracts and deployment schedule.YahooChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In SightChronoScale expanded AI infrastructure contracts, including a new customer agreement, and completed the sale of its Ekso Bionics business to Wandercraft. The company projects an annualized revenue run rate of $1 billion by the third quarter of 2027, subject to deployment and capital availability. Shares rose 1.76% to $19.70 on Friday.Investing.comChronoScale stock jumps on $1B revenue target from AI dealsChronoScale shares rose 3% after-hours following an announcement of expanded customer agreements targeting $1 billion in annualized revenue by Q3 2027. The company also sold its Ekso Bionics business unit to focus on AI infrastructure. Revenue achievement remains subject to deployment and capital risks.Investing.comChronoScale signs new AI contracts, targets $1B revenueChronoScale Holdings announced new AI infrastructure contracts with an existing and a new customer, projecting annualized run-rate revenue of $1 billion by Q3 2027. The company also sold its Ekso Bionics business unit to focus on compute and AI infrastructure. The target is subject to deployment, power, and capital risks.Crypto BriefingChronoScale lands new AI infrastructure deals, sets $1 billion revenue target for Q3 2027ChronoScale Holdings reported contracted run-rate revenue of $1 billion, reaching the milestone by extending and signing new AI infrastructure deals. The company also announced the sale of its Ekso Bionics exoskeleton business and set a $1 billion revenue target for Q3 2027. It plans to complete a 50 MW Microsoft deployment by Q1 2027.The future of tradingChronoScale Announces Agreements Bringing Total Company Contracted Run-Rate Revenue to $1 Billion and Sale of Ekso Bionics Business UnitChronoScale expanded an existing AI infrastructure customer agreement and signed a new one, increasing its contracted deployment pipeline. The agreements, plus existing contracts, provide for $1 billion in annualized run-rate revenue by calendar Q3 2027. The company also completed the sale of its Ekso Bionics business unit to focus on AI infrastructure.YahooChronoScale Announces Agreements Bringing Total Company Contracted Run-Rate Revenue to $1 Billion and Sale of Ekso Bionics Business UnitChronoScale announced expanded agreements with existing and new AI infrastructure customers, raising its contracted deployment pipeline. The agreements, plus existing contracts, project annualized run-rate revenue of $1 billion by calendar Q3 2027. The company also completed the sale of its Ekso Bionics business unit to focus on AI infrastructure.Stock TitanChronoScale AI contracts target $1B run rate by Q3 2027ChronoScale announced expanded agreements with existing and new AI infrastructure customers, raising its contracted deployment pipeline. The agreements, plus existing contracts, target an annualized run-rate revenue of $1 billion by Q3 2027. The company also completed the sale of its Ekso Bionics business unit.The Mercury NewsMarin County’s Ekso Bionics faces uncertain future after AI pivotEkso Bionics' parent company, ChronoScale, committed May 29 to selling its wholly owned Ekso Bionics business and focusing on its cloud computing subsidiary, with completion expected in the first fiscal quarter. Ekso reported 2025 revenue of $12.8 million and a $11.7 million net loss. The San Rafael site's future remains undisclosed.PR NewswirePhysiotherapy Equipment Market worth $8.37 billion by 2031 - Exclusive Report by MarketsandMarkets™MarketsandMarkets projects the physiotherapy equipment market to grow from $6.11 billion in 2026 to $8.37 billion by 2031, a 6.5% CAGR. North America holds the largest share at 30-35% in 2025, and the musculoskeletal & orthopedic segment dominates by application.